Gilead exercised its option to exclusively license KT-200, a preclinical oral CDK2 molecular-glue degrader developed by Kymera Therapeutics. The move follows an earlier June 2025 option and comes as CDK2-targeting strategies expand amid setbacks and uneven performance from first-wave approaches in the clinic. Kymera characterized KT-200 as a selective degrader of CDK2 designed to reduce toxicity risks seen with broader cell-cycle kinase inhibition. Gilead plans IND-enabling work, positioning KT-200 for potential human testing next year. Separately, the broader protein-degrader push is extending across major oncology pipelines, including new collaborations that blend degrader payloads with antibody targeting to improve therapeutic windows.